Insights from a real-world cohort study examining HER2-low status in the CDK4/6 inhibitor era, conducted in collaboration with AstraZeneca, are presented in the accompanying recorded summary.

The key insights from a 1,067-patient real-world cohort—covering survival outcomes, treatment patterns, and the clinical relevance of HER2-Low status in the CDK4/6 inhibitor era - are presented in the accompanying recorded summary

More info: https://ksm.upnext.dev/wp-content/uploads/2025/11/Poster.mp4